KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arbutus Biopharma (ABUS) EBT Margin (2016 - 2025)

Arbutus Biopharma (ABUS) has disclosed EBT Margin for 13 consecutive years, with 421.6% as the latest value for Q4 2025.

  • Quarterly EBT Margin rose 37249.0% to 421.6% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 242.77% through Dec 2025, up 88948.0% year-over-year, with the annual reading at 242.77% for FY2025, 89027.0% up from the prior year.
  • EBT Margin hit 421.6% in Q4 2025 for Arbutus Biopharma, up from 1461.25% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 23.3% in Q2 2025 to a low of 1472.89% in Q3 2024.
  • Historically, EBT Margin has averaged 672.78% across 5 years, with a median of 619.31% in 2021.
  • Biggest five-year swings in EBT Margin: tumbled -104129bps in 2024 and later surged 116976bps in 2025.
  • Year by year, EBT Margin stood at 665.03% in 2021, then soared by 47bps to 351.19% in 2022, then crashed by -156bps to 900.33% in 2023, then grew by 12bps to 794.09% in 2024, then soared by 47bps to 421.6% in 2025.
  • Business Quant data shows EBT Margin for ABUS at 421.6% in Q4 2025, 1461.25% in Q3 2025, and 23.3% in Q2 2025.